Bellicum Pharmaceuticals Inc.

1.42+0.0514+3.76%Vol 19.23K1Y Perf -55.13%
Aug 11th, 2022 15:36 DELAYED
BID1.42 ASK1.45
Open1.34 Previous Close1.37
Pre-Market- After-Market1.35
 - -  -0.07 -4.93%
Target Price
5.00 
Analyst Rating
Strong Buy 1.00
Potential %
252.11 
Finscreener Ranking
★★★★★     63.50
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★+     57.72
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     54.75
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
13.82 
Earnings Rating
Buy
Market Cap12.22M 
Earnings Date
11th Aug 2022
Alpha-0.07 Standard Deviation0.19
Beta1.44 

Today's Price Range

1.341.44

52W Range

1.004.04

5 Year PE Ratio Range

-2.90-1.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
2.90%
1 Month
33.96%
3 Months
-0.70%
6 Months
-1.39%
1 Year
-55.13%
3 Years
-87.21%
5 Years
-98.22%
10 Years
-

TickerPriceChg.Chg.%
BLCM1.420.05143.76
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
-
-96.80
-95.80
-12 195.30
-82.36
RevenueValueIndustryS&P 500US Markets
5.50M
0.64
21.99
69.70
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.25-
Q04 2021--0.27-
Q03 2021-0.07-
Q02 2021--0.22-
Q01 2021--0.89-
Q04 2020--3.05-
Q03 2020-3.29-2.5821.58
Q02 2020--2.47-
Earnings Per EndEstimateRevision %Trend
12/2020 QR-1.0568.75Positive
12/2020 QR-3.3674.15Positive
12/2022 FY-1.8218.39Positive
12/2023 FY-1.4826.00Positive
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume19.23K
Shares Outstanding8.61K
Shares Float7.53M
Trades Count118
Dollar Volume27.03K
Avg. Volume25.24K
Avg. Weekly Volume26.90K
Avg. Monthly Volume22.92K
Avg. Quarterly Volume25.91K

Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM) stock closed at 1.42 per share at the end of the most recent trading day (a 3.76% change compared to the prior day closing price) with a volume of 19.23K shares and market capitalization of 12.22M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 107 people. Bellicum Pharmaceuticals Inc. CEO is Richard A. Fair.

The one-year performance of Bellicum Pharmaceuticals Inc. stock is -55.13%, while year-to-date (YTD) performance is -4.7%. BLCM stock has a five-year performance of -98.22%. Its 52-week range is between 1 and 4.04, which gives BLCM stock a 52-week price range ratio of 13.82%

Bellicum Pharmaceuticals Inc. currently has a PE ratio of -39.80, a price-to-book (PB) ratio of 0.59, a price-to-sale (PS) ratio of 1.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -16.40%, a ROC of -264.27% and a ROE of -227.08%. The company’s profit margin is -82.36%, its EBITDA margin is -95.80%, and its revenue ttm is $5.50 Million , which makes it $0.64 revenue per share.

Of the last four earnings reports from Bellicum Pharmaceuticals Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bellicum Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Bellicum Pharmaceuticals Inc. is Strong Buy (1), with a target price of $5, which is +252.11% compared to the current price. The earnings rating for Bellicum Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bellicum Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bellicum Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.43, ATR14 : 0.12, CCI20 : 101.17, Chaikin Money Flow : 0.05, MACD : 0.05, Money Flow Index : 68.40, ROC : 14.52, RSI : 44.88, STOCH (14,3) : 68.29, STOCH RSI : 1.00, UO : 48.89, Williams %R : -31.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bellicum Pharmaceuticals Inc. in the last 12-months were: James F. Brown (Option Excercise at a value of $0), James M. Daly (Option Excercise at a value of $0), Jon P. Stonehouse (Option Excercise at a value of $0), Judith Klimovsky (Option Excercise at a value of $0), Reid M. Huber (Option Excercise at a value of $0), Stephen R. Davis (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Bellicum Pharmaceuticals Inc.

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (Rivo-cel) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.

CEO: Richard A. Fair

Telephone: +1 832 384-1100

Address: 2130 West Holcombe Boulevard, Houston 77030, TX, US

Number of employees: 107

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

59%41%


News

Stocktwits